NCT01491802 - Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

COPD

Interventions

DRUG

LAMA/LABA

GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.

DRUG

LAMA

GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks

Trial Locations (1)

K7L 2V7

Respiratory Investigation Unit at Kingston General Hospital, Kingston